Seroatlas · Human Serome Atlas

ASPHD2

Aspartate beta-hydroxylase domain-containing protein 2

Also known as: ASPH2_HUMAN, FLJ39838

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q6ICH7
Gene: ASPHD2
Ensembl: ENSG00000128203
Chromosome: 22
Canonical length: 369 aa
Protein class: Predicted membrane proteins

OverviewNCBI Gene

Predicted to enable dioxygenase activity and metal ion binding activity. Located in membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

369 residues, UniProt reviewed canonical sequence.

>Q6ICH7|ASPHD2
     1  MVWAPLGPPR TDCLTLLHTP SKDSPKMSLE WLVAWSWSLD GLRDCIATGI QSVRDCDTTA
    61  VITVACLLVL FVWYCYHVGR EQPRPYVSVN SLMQAADANG LQNGYVYCQS PECVRCTHNE
   121  GLNQKLYHNL QEYAKRYSWS GMGRIHKGIR EQGRYLNSRP SIQKPEVFFL PDLPTTPYFS
   181  RDAQKHDVEV LERNFQTILC EFETLYKAFS NCSLPQGWKM NSTPSGEWFT FYLVNQGVCV
   241  PRNCRKCPRT YRLLGSLRTC IGNNVFGNAC ISVLSPGTVI TEHYGPTNIR IRCHLGLKTP
   301  NGCELVVGGE PQCWAEGRCL LFDDSFLHAA FHEGSAEDGP RVVFMVDLWH PNVAAAERQA
   361  LDFIFAPGR

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against ASPHD2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Unknown
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.34
Highest tissue expression: 19 nTPM

Expression across tissuesHPA

Tissue

cerebellum: 19 nTPM
basal ganglia: 18 nTPM
skin: 10 nTPM
cerebral cortex: 7.7 nTPM
stomach: 7.6 nTPM
pituitary gland: 6.2 nTPM

Single-cell type

foveolar cells: 37 nCPM
early spermatids: 35 nCPM
late spermatids: 35 nCPM
brain inhibitory neurons: 29 nCPM
brain excitatory neurons: 27 nCPM
retinal bipolar cells: 25 nCPM

Immune cell

non-classical monocyte: 5.3 nTPM
intermediate monocyte: 3.1 nTPM
plasmacytoid DC: 2.2 nTPM
myeloid DC: 2.1 nTPM
classical monocyte: 1.1 nTPM
MAIT T-cell: 0.9 nTPM

Brain region

basal ganglia: 36 nTPM
cerebellum: 21 nTPM
cerebral cortex: 19 nTPM
hippocampal formation: 15 nTPM
hypothalamus: 15 nTPM
amygdala: 12 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.54
gnomAD pLI: 0.46
gnomAD missense Z: 1.9
DepMap mean gene effect: -0.03
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Molecular functions

Cellular components

membrane

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads ASPHD2 as an antibody target. Whether an autoantibody or antibody against ASPHD2 could matter depends on whether native ASPHD2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

ASPHD2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label ASPHD2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...